In tumor cells, elevated expression of β-catenin can prevent spontaneous T-cell activation and infiltration into the tumor microenvironment, thereby contributing to resistance against immune checkpoint inhibitors, such as PD-1 and CTLA4 therapies. The gene discussed is CTLA4; the disease is neoplasm.